Acute Respiratory Failure – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Respiratory Failure – Drugs In Development, 2024 report and make more profitable business decisions.
Acute respiratory failure is when lungs become suddenly unable to provide enough oxygen to the blood. Symptoms of respiratory failure include shortness of breath, tachypnea, extreme tiredness, heart palpitations, restlessness, and pale skin. It can be caused by insufficient blood flow to the lungs; blockage, scarring, or fluid in the lungs; or inability to breathe. It can be diagnosed by testing the amount of oxygen and carbon dioxide in blood via pulse oximetry and arterial blood gas (ABG) test; X-rays, CT scans, and EKG can also be used for diagnosis. Mechanical ventilation, extracorporeal membrane oxygenation (ECMO), oxygen therapy, and fluids are used for treatment.
The Acute Respiratory Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Respiratory Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Failure and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Respiratory Failure | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Respiratory Failure therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Respiratory Failure pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Respiratory Failure treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Asklepion Pharmaceuticals LLCAstraZeneca Plc
Genentech USA Inc
Kiniksa Pharmaceuticals Ltd
Partner Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Respiratory Failure reports